A Nobel Prize-winning chemist, Carolyn Bertozzi, is making a comeback to the Eli Lilly and Company's board of directors, effective December 8, 2025. This news has sparked excitement within the scientific community, as Bertozzi's expertise and groundbreaking work in targeted medicine development, particularly in cancer research, will undoubtedly bring immense value to the board's Science and Technology and Ethics and Compliance committees.
David A. Ricks, Lilly's chair and CEO, expressed his enthusiasm, stating, "Carolyn's perspective will be invaluable as we continue to pioneer new approaches in oncology and immunology. We're thrilled to have her back on board as we strive to deliver more breakthrough medicines to patients."
Currently, Bertozzi holds multiple prestigious positions, including the Baker Family director of Sarafan ChEM-H and Anne T. and Robert M. Bass professor in the School of Humanities and Sciences at Stanford University. She is also an Investigator of the Howard Hughes Medical Institute, further solidifying her reputation as a leading scientist.
Bertozzi's research accomplishments have earned her numerous honors and awards, and she is an elected member of the National Academy of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences. Her previous tenure on Lilly's board from 2017 to 2021 further highlights her commitment to the company and its mission.
Lilly, a medicine company with a rich history spanning nearly 150 years, has been at the forefront of life-changing discoveries. Their medicines have helped tens of millions of people worldwide, and they continue to harness the power of biotechnology, chemistry, and genetic medicine to address some of the most significant health challenges of our time. From redefining diabetes care to advancing the fight against Alzheimer's disease and transforming cancer treatment, Lilly's scientists are dedicated to making a positive impact on global health.
As Bertozzi rejoins the board, the company's commitment to innovation and diversity in clinical trials remains unwavering. They strive to ensure their medicines are accessible and affordable, reflecting their dedication to improving the lives of millions more people.
However, it's important to note that research and development, as well as the manufacturing process, come with inherent risks and uncertainties. Lilly acknowledges these challenges and has outlined them in their Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Despite these potential hurdles, the company remains optimistic about the future and the impact of their initiatives.
As Bertozzi returns to the board, the scientific community eagerly anticipates the insights and contributions she will bring to Lilly's ongoing efforts. Her expertise and perspective will undoubtedly play a crucial role in shaping the future of medicine and improving the lives of patients worldwide.
What do you think about the return of Carolyn Bertozzi to Lilly's board? Do you believe her expertise will significantly impact the company's future initiatives? Share your thoughts in the comments below!
